129 related articles for article (PubMed ID: 16965869)
1. Do prostate cancer patients want to choose their own radiation treatment?
van Tol-Geerdink JJ; Stalmeier PF; van Lin EN; Schimmel EC; Huizenga H; van Daal WA; Leer JW
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1105-11. PubMed ID: 16965869
[TBL] [Abstract][Full Text] [Related]
2. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being.
van Tol-Geerdink JJ; Leer JW; van Lin EN; Schimmel EC; Huizenga H; van Daal WA; Stalmeier PF
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):442-8. PubMed ID: 17765404
[TBL] [Abstract][Full Text] [Related]
3. Do patients with localized prostate cancer treatment really want more aggressive treatment?
van Tol-Geerdink JJ; Stalmeier PF; van Lin EN; Schimmel EC; Huizenga H; van Daal WA; Leer JW
J Clin Oncol; 2006 Oct; 24(28):4581-6. PubMed ID: 17008699
[TBL] [Abstract][Full Text] [Related]
4. Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy.
Stalmeier PF; van Tol-Geerdink JJ; van Lin EN; Schimmel E; Huizenga H; van Daal WA; Leer JW
J Clin Oncol; 2007 Jul; 25(21):3096-100. PubMed ID: 17634489
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.
Jereczek-Fossa BA; Vavassori A; Fodor C; Santoro L; Zerini D; Cattani F; Garibaldi C; Cambria R; Fodor A; Boboc GI; Vitolo V; Ivaldi GB; Musi G; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):784-94. PubMed ID: 18191332
[TBL] [Abstract][Full Text] [Related]
7. Choose wisely: therapeutic decisions and quality of life in patients with prostate cancer.
O'Rourke ME
Clin J Oncol Nurs; 2007 Jun; 11(3):401-8. PubMed ID: 17623624
[TBL] [Abstract][Full Text] [Related]
8. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703
[TBL] [Abstract][Full Text] [Related]
9. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
[TBL] [Abstract][Full Text] [Related]
12. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.
Schneider U; Lomax A; Besserer J; Pemler P; Lombriser N; Kaser-Hotz B
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):892-7. PubMed ID: 17459608
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
[TBL] [Abstract][Full Text] [Related]
14. Evaluating a decision aid for patients with localized prostate cancer in clinical practice.
Isebaert S; Van Audenhove C; Haustermans K; Junius S; Joniau S; De Ridder K; Van Poppel H
Urol Int; 2008; 81(4):383-8. PubMed ID: 19077396
[TBL] [Abstract][Full Text] [Related]
15. Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer.
Luo C; Yang CC; Narayan S; Stern RL; Perks J; Goldberg Z; Ryu J; Purdy JA; Vijayakumar S
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1253-62. PubMed ID: 17145540
[TBL] [Abstract][Full Text] [Related]
16. Patient preferences for management of localized prostate cancer.
Mazur DJ; Hickam DH
West J Med; 1996; 165(1-2):26-30. PubMed ID: 8855681
[TBL] [Abstract][Full Text] [Related]
17. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
Zelefsky MJ; Kattan MW; Fearn P; Fearon BL; Stasi JP; Shippy AM; Scardino PT
Urology; 2007 Aug; 70(2):283-7. PubMed ID: 17826490
[TBL] [Abstract][Full Text] [Related]
19. Multiple physician recommendations for prostate cancer treatment: a Pandora's box for patients?
Underwood W; Orom H; Poch M; West BT; Lantz PM; Chang SS; Fowke JH
Can J Urol; 2010 Oct; 17(5):5346-54. PubMed ID: 20974025
[TBL] [Abstract][Full Text] [Related]
20. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
